Berberis aquifolium, Berberis aristata, Argemone mexicana, Berberine
Berberine, or Barberis aristata, is a widespread alkaloid in traditional Chinese medicine. Its source is in the extraction of various plants used in traditional Chinese medicine. Its main benefit is reducing insulin resistance and improving biomarkers of type II diabetes, such as fasting glucose and glycosylated hemoglobin.
- Origin: Plant Based
- Source: Itself
- Type: Alkaloid Chemical Compound
- Age Range: Adults (18-60), Seniors (>60)
- Toxicity: May be toxic in high doses
- Outcomes: Diabetes & Blood Sugar, Blood Sugar Control
What are Berberine benefits?
Barberine is a plant-based substance that is considered herbal and is widely used in traditional Chinese medicine. Its major benefits are breaking down blood sugar, helping with insulin resistance. In addition, it reduces sugar production in the liver and improves hormone function. A great ally in the treatment of diabetes, it also acts on blood pressure and wound healing, and protects the brain from degenerative diseases. Because it is extracted from plants, there are no food sources with this alkaloid, so check out our quiz to find out if this nutraceutical fits your needs!
Table of relations
Published articles about Berberine and Blood Sugar Control
6 months of treatment with 2g inositol to women with hirsutism was associated with reductions in the symptoms directly as well as improvements in insulin sensitivity.
The Combined Therapy With Myo-inositol And D-chiro-inositol Reduces The Risk Of Metabolic Disease In PCOS Overweight Patients Compared To Myo-inositol Supplementation Alone
Supplementation of myo-inositol by itself at 2g daily for a period of six months in women with PCOS was associated with improvements in diastolic blood pressure. The combination with D-chiroinositol was the same at a lower dose (550mg and 13.8mg, respectively) when measured at six months, but seemed to act faster as inositol at 2g required six months to be fully effective.
Effects Of Inositol On Ovarian Function And Metabolic Factors In Women With PCOS: A Randomized Double Blind Placebo-controlled Trial
200mg of inositol daily (in two divided doses of 100mg) for a period of 12 weeks in women with PCOS was ineffective in improving the glucose metabolic markers yet was effective in reducing body weight and improving fertility.
Metabolic And Hormonal Effects Of Myo-inositol In Women With Polycystic Ovary Syndrome: A Double-blind Trial
Supplementation of 4,000mg inositol daily for a period of 12-16 weeks in women with PCOS was able to improve tolerance to glucose and glucose handling (as well as reduce the amount of insulin secreted in response to a meal) with minor benefits to cardiovascular health as well.
Supplementation of myo-inositol at 2g twice daily for the course of one year in postmenopausal women with metabolic syndrome was associated with improvements on all metabolic parameters measured (cardiovascular health and glucose metabolism) although no influence on weight was noted.
Inositol Administration Reduces Oxidative Stress In Erythrocytes Of Patients With Polycystic Ovary Syndrome
Supplementation of 1,200mg Myo-inositol daily for a period of 12 weeks in normal weight women (22-30yrs) with PCOS was able to decrease weight (−1.83+/-1.86kg, very unreliable in magnitude) and improved markers of glucose and androgen metabolism. An improvement in oxidative biomarkers was also noted (GSH in red blood cells).
Randomized, Double Blind Placebo-controlled Trial: Effects Of Myo-inositol On Ovarian Function And Metabolic Factors In Women With PCOS
4g of inositol daily for a period of 16 weeks in women with PCOS was ineffective in improving parameters of insulin sensitivity while it was sufficient to improve biomarkers of steroid metabolism and fertility. Weight was decreased in all subjects who were not morbidly obese.
Differential Insulin Response To Myo-inositol Administration In Obese Polycystic Ovary Syndrome Patients
Supplementation of 2,000mg inositol (INOFERT) once daily for eight weeks in obese women with PCOS was able to improve insulin sensitivity and other biomarkers of glucose metabolism only in those with higher circulating insulin concentrations. No placebo control was used in this study.
Myo-inositol Treatment Increases Serum Plasmalogens And Decreases Small Dense LDL, Particularly In Hyperlipidemic Subjects With Metabolic Syndrome
Two weeks supplementation of _myo_-inositol at 5g (first week) and 10g (second week) was able to increase circulating levels of choline plasmalogen, which is thought to be the reason behind a reduction in LDL-C. These changes were not present in persons without metabolic syndrome.
5g psyllium taken thrice a day for 6 weeks was able to significantly reduce glucose and all improve all parameters of a lipid panel in diabetic persons relative to placebo; treatment was well tolerated.
Supplementation of 14g of psyllium fiber daily for six weeks was associated with a significantly reduced absorption of glucose (12.2%) and a reduction in other parameters of glucose metabolism including insulin (5%), HbA1c (3.8%), 24-hour urinary glucose (22.5%), fructosamine (), and uric acid (10.9%). Some improvements were also noted in the lipid profile.
Cholesterol-lowering Effects Of Soluble-fiber Cereals As Part Of A Prudent Diet For Patients With Mild To Moderate Hypercholesterolemia
Supplementation of 10g psyllium husk via cereal in persons with high cholesterol for 6 weeks failed to influence hematological parameters and body weight while reducing total cholesterol and LDL-C.
Effects Of Dietary Fiber And Low Glycemic Index Diet On Glucose Control In Subjects With Type 2 Diabetes Mellitus
Assessment of 7 trials using psyllium supplement and/or a low glycemic diet for diabetes management concluded that psyllium was possibly useful as an adjuvant treatment for blood glucose and HbA1c in diabetics on drugs who may require further therapy to reduce glucose.
In diabetic patients, Berberine at 0.5-1.5g daily for an average period of 12 weeks was associated with minor to moderate improvements on all measured glucose and lipid parameters; rivalling oral hypoglycemics in potency
Berberine in isolation at 1g for 3 months was able to reduce triglycerides and fasting glucose levels in type II diabetics. Total cholesterol and LDL also decreased, and an increase in glucose disposal rate was seen. Insulin sensitivity showed a trend for improvement, but did not reach statistical significance.
184 patients with nonalcoholic fatty liver disease were randomized to one of three arms for 16 weeks: lifestyle intervention alone, lifestyle interventions plus 15mg pioglitazone daily, or lifestyle interventions plus 0.5g berberine three times a day. Berberine plus lifestyle changes significantly improved liver fat content, BMI, HOMA-IR, total cholesterol, and triglycerides significantly more than lifestyle interventions alone. The berberine group tended to have minor digestive issues that tended to resolve 2 weeks into the study.
Effect Of Berberine Administration On Metabolic Syndrome, Insulin Sensitivity, And Insulin Secretion
24 people with metabolic syndrome were randomized to placebo or 0.5g berberine three times a day for three months. Decrease in waist circumference in females only, systolic blood pressure, triglycerides, area under the curve of glucose and insulin, and Matsuda index were all seen to be significant in the berberine group versus placebo.
Biotin Supplementation Reduces Plasma Triacylglycerol And VLDL In Type 2 Diabetic Patients And In Nondiabetic Subjects With Hypertriglyceridemia
Supplementation of 15mg biotin in subjects with high triglycerides, with or without type II diabetes, appeared to reduce serum triglycerides and vLDL over the course of 28 days therapy. There were no other biochemical changes noted, and while there was a trend to reduce BMI it did not reach significance.
Supplementation of chromium to type II diabetics for 28 weeks noted a reduction in blood glucose relative to baseline and placebo, and the minor changes in HbA1c and insulin turned out to be significant due to an increase seen in placebo. Weight and blood pressure were not significantly different, nor were any parameter of lipid metabolism measured.
The Effects Of Inorganic Chromium And Brewer's Yeast Supplementation On Glucose Tolerance, Serum Lipids And Drug Dosage In Individuals With Type 2 Diabetes
Low dose chromium supplementation (23.3mcg) via Brewer's Yeast and 200mcg chromium as trichloride for eight weeks in type II diabetics both appeared to reduce both fasting and postprandial blood glucose (75g glucose tolerance test) and was able to reduce fructosamine as well.
The Influence Of Chromium Chloride-containing Milk To Glycemic Control Of Patients With Type 2 Diabetes Mellitus: A Randomized, Double-blind, Placebo-controlled Trial
The addition of 200mcg chromium (as chloride) to milk powder, relative to a milk powder placebo, in type II diabetics already on medication (gliclazide) noted that there was a reduction in blood glucose, insulin, and improvement in insulin sensitivity over the course of 16 weeks in men only. Acute insulin response following an oral glucose tolerance test (10 minutes after) was unaffected in both sexes.
Elevated Intakes Of Supplemental Chromium Improve Glucose And Insulin Variables In Individuals With Type 2 Diabetes
4 months supplementation of 200mcg or 1,000mcg chromium (as picolinate) in type II diabetics was able to reduce fasting and postprandial blood glucose (higher dose only), fasting and postprandial insulin (both groups equally), HbA1c (higher dose only), and total cholesterol (higher dose only) with no influence on HDL nor body weight.
In overweight women reporting intense carbohydrate cravings at least twice a week, supplementation of 1,000mcg chromium appeared to reduce hunger and cravings over the course of weight weeks which resulted in a greater reduction in overall food intake (25%) than did placebo (8%). This reduction in food intake led to weight loss, but was independent of any changes in glucose metabolism.
A Double-blind, Randomized Pilot Trial Of Chromium Picolinate For Binge Eating Disorder: Results Of The Binge Eating And Chromium (BEACh) Study
Six months supplementation of chromium as picolinate (600µg or 1000µg) was able to nonsignificantly reduce symptoms of binge eating disorder (binge frequency) and weight relative to placebo, while HbA1c and blood glucose also failed to reach statistically significant reductions despite trends to do so.
Effects Of Short-term Chromium Supplementation On Insulin Sensitivity And Body Composition In Overweight Children: Randomized, Double-blind, Placebo-controlled Study
400mcg chromium given to overweight children who were also given exercise and diet plans (relative to diet and exercise paired with placebo) over the course of six weeks failed to reduce bodyweight relative to placebo (at the P level of 0.05) but the reduction in fat mass and increase in lean mass was greater with chromium than with placebo. Insulin sensitivity was improved to a statistically significant degree, but no other health variable was beneficially influenced.
Effect Of Resistance Training With Or Without Chromium Picolinate Supplementation On Glucose Metabolism In Older Men And Women
In otherwise healthy but overweight aged adults, the combination of chromium plus resistance training (relative to placebo and training) over 13 week dosed at 1,000mcg failed to augment the benefits of exercise (in reducing insulin AUC following an oral glucose tolerance test) and did not exert any hypoglycemic actions.
Influence Of Chromium-enriched Yeast On Blood Glucose And Insulin Variables, Blood Lipids, And Markers Of Oxidative Stress In Subjects With Type 2 Diabetes Mellitus
In obese type II diabetic (on medication) subjects given supplemental chromium via yeast (400 micrograms daily) for 12 weeks was associated with a decrease in blood glucose relative to placebo but all other measured biomarkers were unchanged, although a reduction in insulin and weight in both groups tended to decrease further with chromium. Lipid peroxidation (MDA) was unaffected and the antioxidant enzymes were mostly unaffected, although a decrease in glutathoine and glutathione peroxidase seen at the end of the trial in placebo was mitigated with chromium.
Supplementation of 1,000mcg chromium daily for three months in type II diabetics was able to shorten QTc intervals, suggesting a cardioprotective effect (as prolonged QTc intervals are indicative of cardiovascular mortality). Aside from insulin (which was also reduced), no other parameter was influenced.
Antioxidant Effects And Insulin Resistance Improvement Of Chromium Combined With Vitamin C And E Supplementation For Type 2 Diabetes Mellitus
In type II diabetics with an HbA1c over 8.5% given 1mg of chromium via yeast, supplementation was associated with a reduction in blood glucose (11%) and HbA1c (0.7%, from 10.2% to 9.5%) alongside an increase in insulin sensitivity. Lipid peroxidation, as assessed by TBARS, was also reduced with chromium by 18.7%. An increase in glutathoine peroxidase was noted, but catalase and SOD were unaffected.
In 11 middle aged obese women given 400mcg chromium (as picolinate) daily for eight weeks, there was no observable change in the anti-HMdU antibody suggesting no DNA damage from supplementation.
Effect Of Chromium On Glucose And Lipid Profiles In Patients With Type 2 Diabetes; A Meta-analysis Review Of Randomized Trials
A meta-analysis on chromium in type II diabetics where supplementation lasted for over three months noted that, relative to placebo, there was a mild but significant reduction in blood glucose. HbA1c and all biomarkers of lipid metabolism, as well as weight, were all unaffected. This meta-analysis was restricted to type II diabetics and the duration of at least three months, but at times included studies containing chromium enriched yeast and biotin supplementation alongside the chromium.
Characterization Of The Metabolic And Physiologic Response To Chromium Supplementation In Subjects With Type 2 Diabetes Mellitus
Supplementation of 1mg chromium (in the form of chromium picolinate) in two divided doses daily for 24 weeks in type II diabetics noted that while there was a trend to increase insulin sensitivity, this was not statistically significant and only 46% of persons were considered responders. No other changes were noted in diet, glucose metabolism, and the response to chromium was more associated with baseline insulin resistance rather than the kinetics of chromium after ingestion.
Chromium Supplementation Does Not Improve Glucose Tolerance, Insulin Sensitivity, Or Lipid Profile: A Randomized, Placebo-controlled, Double-blind Trial Of Supplementation In Subjects With Impaired Glucose Tolerance
Supplementation of 400mcg chromium (as picolinate) twice daily in obese participants with impaired glucose tolerance failed to exert any appreciable benefit relative to placebo over the course of three months.
The addition of 400 or 800μg chromium (as picolinate) to a test meal containing 75g carbohydrate from breads noted that there was no significant influence on postprandial metabolism when assessing the whole group, but the subjects could be divided into responders and nonresponders where said responders reduced the glucose AUC by 30-36% (lower dose being more effective). Insulin was not affected in any person, and the nonresponders appeared to have a more meat and milk based diet than a plant based one. Nonresponders also had a significantly higher iron and transferrin content in the blood (transferrin saturation and ferritin content similar).
The Effects Of Inorganic Chromium And Brewer's Yeast On Glucose Tolerance, Plasma Lipids, And Plasma Chromium In Elderly Subjects
In otherwise healthy free living adults, supplementation of chromium either as trichloride (200mcg chromium) or as yeast (5g yeast containing 10.8mcg chromium) failed to significantly influence any measured parameter in the blood despite an increase of chromium in the blood from trichloride including glucose tolerance to an oral glucose tolerance test.
Beneficial Effects Of Oral Chromium Picolinate Supplementation On Glycemic Control In Patients With Type 2 Diabetes: A Randomized Clinical Study
In older adults with evidence of memory decline, 1,000mcg chromium (as picolinate) daily for 12 weeks failed to influence glucose metabolism and did not influence depressive symptoms. Despite no influence on memory over the 12 weeks, there appeared to be significantly less inclusion errors during testing and increased activity in some regions of the right half of the brain during memory testing.
Supplementation of 1mg chromium as picolinate in obese adults over the course of 24 weeks failed to influence body weight either alone or in combination with nutritional education (teaching participants to eat better) and no other parameter in the blood or via CT scans was modified with supplementation.
Chromium Effects On Glucose Tolerance And Insulin Sensitivity In Persons At Risk For Diabetes Mellitus
Supplementation of chromium picolinate at 500mcg or 1,000mcg for six months in persons at risk for type II diabetes has failed to influence any biomarkers of glucose metabolism and was said to not confer any protection against the development of type II diabetes.
Supplementation of 600mcg chromium daily for a month failed to significantly modify glycogen depletion, concentrations, or resynthesis rates surrounding exercise in untrained or minorly trained men relative to placebo. Lactate AUC was higher with chromium intake relative to placebo.
Effects Of Carbohydrate And Chromium Ingestion During Intermittent High-intensity Exercise To Fatigue
In otherwise active men given a carbohydrate drink with or without an additional 400mcg chromium (as picolinate) subject to a shuttle run test an hour after the drink, the addition of chromium failed to significantly alter any change that carbohydrate was able to induce relative to water control suggesting no additional benefit.
Chromium Treatment Has No Effect In Patients With Type 2 Diabetes In A Western Population: A Randomized, Double-blind, Placebo-controlled Trial
Six months supplementation of chromium at 400mcg via enriched yeast to type II diabetics already on medications failed to confer any additional benefits, particularly the primary outcome (to see if a 0.5% reduction in HbA1c was reached).
Chromium Picolinate Supplementation Attenuates Body Weight Gain And Increases Insulin Sensitivity In Subjects With Type 2 Diabetes
Supplementation of 1,000µg chromium (as picolinate) alongside sulfonylurea therapy for 10 months in type II diabetic persons noted that, relative to a sulfonylurea/placebo pairing, that chromium resulted in an additional decrease in glucose and free fatty acids in serum without any other significant alterations. There appeared to be an anti-obese effect of chromium, as the 0.9kg weight gain with sulfonylurea therapy was mitigated with chromium coingestion.
Beneficial Effect Of Chromium Supplementation On Glucose, HbA1C And Lipid Variables In Individuals With Newly Onset Type-2 Diabetes
Supplementation of brewers yeast (conferring 42 μg chromium) in newly diagnosed diabetics for three months was able to significantly reduce blood glucose (47.6%), HbA1c (from 9.5% to 6.8%), and systolic blood pressure (12%) while causing some benefit to all lipid parameters except vLDL and HDL relative to placebo.
Chromium supplementation at 1,000mcg daily (as picolinate) increased the acute insulin response to glucose but failed to influence any other measured parameter of metabolic syndrome after 16 weeks supplementation in adults with signs of metabolic syndrome yet no diagnosed diabetes.
Effects Of Chromium Brewer's Yeast Supplementation On Body Mass, Blood Carbohydrates, And Lipids And Minerals In Type 2 Diabetic Patients
In obese type II diabetic subjects given trivalent chromium supplementation via Brewer's Yeast (500mcg chromium) for eight weeks, supplementation was able to exert a minor hypoglycemic effect which failed to reach statistical significance (P=0.08) while trends on other biochemical parameters failed to reach statistical significance.
In Patients With HIV-infection, Chromium Supplementation Improves Insulin Resistance And Other Metabolic Abnormalities: A Randomized, Double-blind, Placebo Controlled Trial
Supplementation of 400mcg chromium (as nicotinate) daily for 16 weeks in persons with HIV who were insulin resistant due to antiretroviral therapy appeared to improve insulin sensitivity and some other measured parameters such as triglycerides and weight when used as adjuvant.
Impact of cooking and digestion, in vitro, on the antioxidant capacity and anti-inflammatory activity of cinnamon, clove and nutmeg
Effectiveness of cinnamon for lowering hemoglobin A1C in patients with type 2 diabetes: a randomized, controlled trial
Effect of ground cinnamon on postprandial blood glucose concentration in normal-weight and obese adults
The advanced glycation end product, Nepsilon-(carboxymethyl)lysine, is a product of both lipid peroxidation and glycoxidation reactions
Carboxymethyl lysine, an advanced glycation end product, and incident diabetes: a case-cohort analysis of the ARIC Study
200mg of Panax Ginseng, taken acutely one hour before endurance testing, was unable to increase physical performance in runners. Lactate production was reduced when measured 60 minutes after the start of exercise.
Korean Red Ginseng (Panax Ginseng C.A. Meyer) Root Fractions: Differential Effects On Postprandial Glycemia In Healthy Individuals
Korean Red Ginseng, given in a cross-over manner to 13 persons over 3 visits to the lab, in either 3g of the ginseng body or 3g of the ginseng rootlets. Ginseng was found to reduce post-prandial glucose when administered as the body, but the rootlets with a higher ginsengoside content were unable to do so.
In type II diabetics given Panax Ginseng at 100-200mg for a period of 8 weeks, improvements in body weight, mood, and glycemic profiles were seen.
Effects Of Korean Red Ginseng On Cardiovascular Risks In Subjects With Metabolic Syndrome: A Double-blind Randomized Controlled Study
12 weeks of 4.5g KRG supplementation in persons with metabolic syndrome noted an increase in HDL-C, but other parameters tested were either not affected or affected to the same extent in placebo
Ginseng And Ginsenoside Re Do Not Improve β-cell Function Or Insulin Sensitivity In Overweight And Obese Subjects With Impaired Glucose Tolerance Or Diabetes
3g of ginseng daily for 2 weeks, and then 8g for the next two weeks, in obese diabetic (or pre-diabetic) adults for 30 days was unable to alter fasting glucose and fasting insulin sensitivity, as well as B-cell function. No circulating levels of ginsenosides were seen despite being advised to consume their final dose 30 minutes before testing.
Single Doses Of Panax Ginseng (G115) Reduce Blood Glucose Levels And Improve Cognitive Performance During Sustained Mental Activity
Cognition as assessed by serial sevens was significantly improved, and blood glucose decreased, after ingestion of 200mg and 400mg G115 extract
64 subjects were divided into placebo or experimental, and the latter given 3g of red ginseng extract for 3 months. Although reductions in blood pressure and improvements in heart health were seen with Ginseng, these were also found in placebo.
Effects Of Panax Ginseng Supplementation On Muscle Damage And Inflammation After Uphill Treadmill Running In Humans
Insulin sensitivity was improved and glucose reduced during an Oral Glucose Tolerance Test (OGTT) and muscle damage induced by downhill running was reduced and inflammation production hindered (assessed via IL-6), after consumption of 20g Red Ginseng extract daily in young healthy athletes.
Effects Of Panax Ginseng, Consumed With And Without Glucose, On Blood Glucose Levels And Cognitive Performance During Sustained 'mentally Demanding' Tasks
200mg and 400mg of 4% ginsenosides can decreaes blood glucose from around 7-12% in otherwise healthy persons within 60-120 minutes after ingestion, as well as increase cognitive function as assessed by serial sevens subtraction; the two do not seem related.
Panax Ginseng Has No Effect On Indices Of Glucose Regulation Following Acute Or Chronic Ingestion In Healthy Volunteers
Two separate studies by the same research group demonstrated that Panax Ginseng had no effect on HbA1c, fasting insulin, or fasting glucose in healthy volunteers.
17mmol Magnesium Orotate daily for 4 weeks was associated with significant improvement on the time it took to complete triathalon-like testing.
Oral Magnesium Supplementation Improves Insulin Sensitivity And Metabolic Control In Type 2 Diabetic Subjects: A Randomized Double-blind Controlled Trial
Magnesium chloride, when correcting a deficiency, is associated with improvements in insulin sensitivity, glucose, and HbA1c. 2.5g Magnesium chloride equates to 450mg elemental magnesium
Effects Of Oral Magnesium Supplementation On Insulin Sensitivity And Blood Pressure In Normo-magnesemic Nondiabetic Overweight Korean Adults
No significant effects were observed in persons with normal magnesium status and without hypertension or pre-diabetes when dosed at 300mg daily
360mg Magnesium daily for 3 months in type II diabetics failed to find any influence on measured parameters.
Magnesium Improves The Beta-cell Function To Compensate Variation Of Insulin Sensitivity: Double-blind, Randomized Clinical Trial
Correcting a magnesium deficiency in nondiabetic and normotensive men (0.66mM to 0.78mM) corrects various pancreatic abnormalities and blood pressure, but no significant influence on weight or triglycerides was noted and the increase in HDL-C failed to reach statistical significance after 3 months.
The Effect Of Magnesium Supplementation On Glucose And Insulin Levels Of Tae-kwan-do Sportsmen And Sedentary Subjects
Glucose was increased at rest and post-fatigue in sportsmen given magnesium relative to sportsmen controls, dose was not given, but was used for 4 weeks.
Oral Magnesium Supplementation Reduces Insulin Resistance In Non-diabetic Subjects - A Double-blind, Placebo-controlled, Randomized Trial
Pre-diabetic (insulin resistant obese persons) that were not magnesium deficient experienced a reduction in fasting blood glucose after 365mg Magnesium Aspartate-Chloride for 6 months. Serum ionized magnesium increased, but erythrocytic and serum were not significant,.
The Effect Of Lowering Blood Pressure By Magnesium Supplementation In Diabetic Hypertensive Adults With Low Serum Magnesium Levels: A Randomized, Double-blind, Placebo-controlled Clinical Trial
A very small increase in HDL but significant reductions in blood pressure observed after 450mg supplementation for 4 months in hypertensive adults with diabetes and low magnesium levels
Oral Zinc Supplementation Does Not Improve Oxidative Stress Or Vascular Function In Patients With Type 2 Diabetes With Normal Zinc Levels
Supplementation of 240mg elemental zinc as gluconate daily for a period of three months in diabetics has failed to provide any additional benefit to circulating biomarkers when the participants were already at adequate zinc stores.
Effect Of Zinc Supplementation On Markers Of Insulin Resistance, Oxidative Stress, And Inflammation Among Prepubescent Children With Metabolic Syndrome
Supplementation of 20mg elemental zinc daily for 8 weeks in obese adolescents who were insulin resistant noted improvements in all biomarkers of glucose metabolism and inflammatory parameters, and a beneficial change was seen in oxidative biomarkers as well as most of the lipid panel (no influence on HDL-C).
Effect Of Zinc Supplementation On Insulin Resistance And Components Of The Metabolic Syndrome In Prepubertal Obese Children
In obese children given 20mg elemental zinc supplementation daily for eight weeks, supplementation was associated with a betterment of biomarkers of glucose metabolism although it was not associated with weight loss nor lipid profiles.
The body's cells use glucose to produce energy. Glucose comes from food and is stored in the body in the form of glycogen (in the muscles and liver) or circulating glucose (in the blood). Cells need the hormone Insulin to capture glucose molecules. The glucose / insulin balance in the blood is essential for the proper functioning of the body's whole metabolism. A change in this metabolism can lead to serious physiological dysfunctions, leading to the development of chronic non-communicable diseases, such as type II diabetes and cardiovascular diseases. There are several classes of compounds that influence this metabolism, these can increase insulin synthesis and secretion, decrease blood glucose levels, reduce the immediate absorption of carbohydrates, regulate the sensitivity of cells to insulin, among others.